News
About the PCSK9 Education and Research Forum
PCSK9 Education and Research Forum is the independent resource on PCSK9 science and its translation into critically important new treatments to lower low density lipoprotein cholesterol (LDL-C), which promise to transform the prognosis of millions of patients with hypercholesterolaemia (cholesterol disorders), accelerated atherosclerotic vascular heart disease and a high risk of premature cardiovascular (CV) death and disability.Aims & ObjectivesMission StatementEditorial BoardPartnership & OutreachForthcoming Meetings
Download Now: New Slide Deck Programme
Available now - first two decks focusing on the main results from FOURIER and ODYSSEY OUTCOMES – two landmark trials in PCSK9 inhibition
Find out more »
ACC Scientific Sessions 2019
What was the PCSK9 news at this year’s Congress?
PCSK9 Forum Inhibitors and Health Economics
The value of PCSK9 inhibition in very high risk patients is a Hot Topic in the light of recent data from the ODYSSEY OUTCOMES Economics Study. How do these data relate to the current clinical pathway used in the European setting?
PCSK9 Forum Editor Professor Anthony Wierzbicki (Guys and St. Thomas’ Hospital London, UK) puts the results in context.
Watch the video
Perspective on the ODYSSEY OUTCOMES Economic Study
Watch the video
PCSK9 inhibitors: How do we weigh up the benefit versus cost of treatment?
Watch the video
Hot Topics
Coronary artery calcium in familial hypercholesterolaemia
Coronary artery calcium may have a role in stratifying short-term risk in patients with familial hypercholesterolaemia (FH, inherited high cholesterol), according to a new study. This noninvasive approach may have value in targeting treatment with a PCSK9 inhibitor to those patients at highest risk.
VIDEO: Is coronary artery calcium a risk assessment too in FH?
Watch the video
VIDEO: Severe FH: how to define?
Watch the video
VIDEO: ESC/EAS Task Force guidance for PCSK9 inhibitors
Watch the video
From the Editors
Did someone say “Beyond LDL-cholesterol”?
PCSK9 Forum Editor Professor John Chapman (Pitié-Salpétrière University Hospital, and Sorbonne University, Paris, France) discusses how ‘OMICS’ technologies could provide a precision medicine approach to managing non-LDL lipids.
Latest Views
Meet our Editorial Board
View all our Editorial Board
Prof John ChapmanResearch Professor at the University of Pierre and Marie Curie
Prof Henry GinsbergDirector, Irving Institute for Clinical and Translational Research
Dr Michel FarnierClinician based at Point Medical, Dijon, France
Prof Frederick RaalDirector, Carbohydrate & Lipid Metabolism Research Unit
Prof Anthony WierzbickiConsultant in Metabolic Medicine/Chemical Pathology
